Dupuytren's: A systems biology disease

Arthritis Research and Therapy

Volumn 13, Issue 5, 2011, Pages

  Rehman, Samrina ^a   Goodacre, Royston ^a   Day, Philip J ^a   Bayat, Ardeshir ^a   Westerhoff, Hans V ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CELL ADHESION MOLECULE; CLOSTRIDIOPEPTIDASE A; COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; CYTOKINE; FREE RADICAL; GROWTH FACTOR; HYPOXANTHINE; METALLOPROTEINASE; MYOGLOBIN; MYOSIN; PERIPLAKIN; PHENYLALANINE 4 MONOOXYGENASE; PROTEIN KINASE B; PROTEOGLYCAN; REACTIVE OXYGEN METABOLITE; RNA 16S; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; XANTHINE OXIDASE;

APOPTOSIS; CARBOHYDRATE METABOLISM; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMOSOME 16; CYTOKINE PRODUCTION; DISEASE COURSE; DUPUYTREN CONTRACTURE; EXTRACELLULAR MATRIX; FASCIOTOMY; FIBROSIS; GENE EXPRESSION; GENETIC ANALYSIS; HISTOLOGY; HISTOPATHOLOGY; HUMAN; ISCHEMIA; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MUSCLE CONTRACTION; MYOFIBROBLAST; OXYGEN TRANSPORT; PALMAR FASCIA; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN SYNTHESIS; PROTEOMICS; QUANTITATIVE STUDY; REVIEW; SIGNAL TRANSDUCTION; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; SYSTEMS BIOLOGY; TRANSCRIPTOMICS; TWO DIMENSIONAL GEL ELECTROPHORESIS; ANIMAL; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; METHODOLOGY;

ANIMALS; DUPUYTREN CONTRACTURE; GENE EXPRESSION PROFILING; HUMANS; PROTEOMICS; REACTIVE OXYGEN SPECIES; SYSTEMS BIOLOGY;

EID: 84858833415     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3438     Document Type: Review

References (106)

1. McFarlane RM, Flint MH. Dupuytren's Disease: Biology and Treatment 1990, New York: Churchill Livingstone.
2. Rayan GM. Dupuytren disease: anatomy, pathology, presentation, and treatment. J Bone Joint Surg Am 2007, 89:189-198. 10.1302/0301-620X.89B2.18161, 17256226.
3. Shih B, Bayat A. Scientific understanding and clinical management of Dupuytren's disease. Nat Rev Rheumatol 2010, 6:715-726. 10.1038/nrrheum.2010.180, 21060335.
4. Meyerding HW, Black JR, Broders AC. The etiology and pathology of Dupuytren's contracture. Surg Gynecol Obstetric 1941, 72:582-590.
5. Seemayer TA, Lagacé R, Schürch W, Thelmo WL. The myofibroblast: biologic, pathologic, and theoretical considerations. Pathol Annu 1980, 15(Pt 1):443-470.
6. Bayat A, McGrouther DA. Management of Dupuytren's disease - clear advice for an elusive condition. Ann R Coll Surg Engl 2006, 88:3-8. 1964087, 16884607.
7. Shaw RB, Chong AKS, Zhang A, Hentz VR, Chang J. Dupuytren's disease: history, diagnosis, and treatment. Plast Reconstr Surg 2007, 120:44e-54e. 10.1097/01.prs.0000278455.63546.03, 17700106.
8. Hindocha S, Stanley JK, Watson S, Bayat A. Dupuytren's diathesis revisited: evaluation of prognostic indicators for risk of disease recurrence. J Hand Surg Am 2006, 31:1626-1634. 10.1016/j.jhsa.2006.09.006, 17145383.
9. Hayton MJ, Gray ICM. Dupuytren's contracture: a review. Curr Orthopaed 2003, 17:1-7.
10. Tse R, Howard J, Wu Y, Gan B. Enhanced Dupuytren's disease fibroblast populated collagen lattice contraction is independent of endogenous active TGF-beta2. BMC Musculoskelet Disord 2004, 5:41. 10.1186/1471-2474-5-41, 534110, 15541177.
11. Drake MJ, Hedlund P, Andersson KE, Brading AF, Hussain I, Fowler C, Landon DN. Morphology, phenotype and ultrastructure of fibroblastic cells from normal and neuropathic human detrusor: Absence of myofibroblast characteristics. J Urol 2003, 169:1573-1576. 10.1097/01.ju.0000054928.34777.37, 12629418.
12. Moyer KE, Banducci DR, Graham WP, Ehrlich HP. Dupuytren's disease: physiologic changes in nodule and cord fibroblasts through aging in vitro. in vitro Plast Reconstr Surg 2002, 110:187-193.
13. Lubahn JD, Pollard M, Cooney T. Immunohistochemical evidence of nerve growth factor in Dupuytren's diseased palmar fascia. J Hand Surg Am 2007, 32:337-342. 10.1016/j.jhsa.2006.12.011, 17336840.
14. Clozel M, Salloukh H. Role of endothelin in fibrosis and antifibrotic potential of bosentan. Ann Med 2005, 37:2-12. 10.1080/07853890410018925, 15902842.
15. Cordova A, Tripoli M, Corradino B, Napoli P, Moschella F. Dupuytren's contracture: an update of biomolecular aspects and therapeutic perspectives. J Hand Surg Br 2005, 30:557-562. 10.1016/j.jhsb.2005.07.002, 16168532.
16. Hnanicek J, Cimburova M, Putova I, Svoboda S, Stritesky J, Kratka K, Sosna B, Horak J. Lack of association of iron metabolism and Dupuytren's disease. J Eur Acad Dermatol Venereol 2008, 22:476-480. 10.1111/j.1468-3083.2007.02506.x, 18194242.
17. Kaur S, Forsman M, Ryhänen J, Knuutila S, Larramendy ML. No gene copy number changes in Dupuytren's contracture by array comparative genomic hybridization. Cancer Genet Cytogenet 2008, 183:6-8. 10.1016/j.cancergencyto.2008.01.018, 18474290.
18. Rehman S, Salway F, Stanley JK, Ollier WER, Day P, Bayat A. Molecular phenotypic descriptors of Dupuytren's disease defined using informatics analysis of the transcriptome. J Hand Surg Am 2008, 33:359-372. 10.1016/j.jhsa.2007.11.010, 18343292.
19. Forsman M, Paakkonen V, Tjaderhane L, Vuoristo J, Kallioinen L, Salo T, Kallioinen M, Ryhanen J. The expression of myoglobin and ROR2 protein in Dupuytren's disease. J Surg Res 2008, 146:271-275. 10.1016/j.jss.2007.06.022, 17996904.
20. Johnston P, Chojnowski AJ, Davidson RK, Riley GP, Donell ST, Clark IM. A complete expression profile of matrix-degrading metalloproteinases in Dupuytren's disease. J Hand Surg Am 2007, 32:343-351. 10.1016/j.jhsa.2006.12.010, 17336841.
21. Lee LC, Zhang AY, Chong AK, Pham H, Longaker MT, Chang J. Expression of a novel gene, MafB, in Dupuytren's disease. J Hand Surg Am 2006, 31:211-218. 10.1016/j.jhsa.2005.09.007, 16473681.
22. O'Gorman D, Wu Y, Seney S, Zhu R, Gan B. Wnt expression is not correlated with beta-catenin dysregulation in Dupuytren's disease. J Negat Results Biomed 2006, 5:13. 10.1186/1477-5751-5-13, 1564412, 16942611.
23. Samuel CS, Hewitson TD. Relaxin in cardiovascular and renal disease. Kidney Int 2006, 69:1498-1502. 10.1038/sj.ki.5000264, 16672919.
24. Maureen DM. Endothelin and endothelin receptor antagonists in systemic rheumatic disease. Arthritis Rheum 2003, 48:1190-1199. 10.1002/art.10895, 12746891.
25. Pan D, Watson HK, Swigart C, Thomson JG, Honig SC, Narayan D. Microarray gene analysis and expression profiles of Dupuytren's contracture. Ann Plast Surg 2003, 50:618-622. 10.1097/01.SAP.0000069066.35253.B3, 12783014.
26. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100:57-70. 10.1016/S0092-8674(00)81683-9, 10647931.
27. Kholodenko BN, Kiyatkin A, Bruggeman FJ, Sontag E, Westerhoff HV, Hoek JB. Untangling the wires: a strategy to trace functional interactions in signaling and gene networks. Proc Natl Acad Sci USA 2002, 99:12841-12846. 10.1073/pnas.192442699, 130547, 12242336.
28. An G, Hunt CA, Clermont G, Neugebauer E, Vodovotz Y. Challenges and rewards on the road to translational systems biology in acute illness: four case reports from interdisciplinary teams. J Crit Care 2007, 22:169-175. 10.1016/j.jcrc.2006.12.011, 1950677, 17548029.
29. Westerhoff HV, Palsson BO. The evolution of molecular biology into systems biology. Nat Biotechnol 2004, 22:1249-1252. 10.1038/nbt1020, 15470464.
30. Ahn AC, Tewari M, Poon C-S, Phillips RS. The limits of reductionism in medicine: could systems biology offer an alternative?. PLoS Med 2006, 3:e208. 10.1371/journal.pmed.0030208, 1459480, 16681415.
31. Katagiri F. Attacking complex problems with the power of systems biology. Plant Physiol 2003, 132:417-419. 10.1104/pp.103.021774, 1540320, 12805572.
32. Spivey A. Systems biology: the big picture. Environ Health Perspect 2004, 112:A938-A943. 1247669, 15598608.
33. Jensen PR, Gugten A, Bier M, Heeswijk W, Rohwer JM, Molenaar D, Workum M, Richard P, Teusink B, Bakker BM, Westerhoff HV. Hierarchies in control. J Biol Systems 1995, 3:139-144.
34. Kahn D, Westerhoff HV. Control theory of regulatory cascades. J Theor Biol 1991, 153:255-285. 10.1016/S0022-5193(05)80426-6, 1686290.
35. Steven Wiley H, Shvartsman SY, Lauffenburger DA. Computational modeling of the EGF-receptor system: a paradigm for systems biology. Trends Cell Biol 2003, 13:43-50. 10.1016/S0962-8924(02)00009-0, 12480339.
36. Schoeberl B, Gaudet S, Albeck JG, Janes K, Sorger PK, Lauffenburger DA. The apoptotic decision process in TNF alpha-stimulated HT-29 cells: a combined computational and experimental approach. Mol Biol Cell 2002, 13:11A-A.
37. Daran-Lapujade P, Rossell S, van Gulik WM, Luttik MA, de Groot MJ, Slijper M, Heck AJ, Daran JM, de Winde JH, Westerhoff HV, Pronk JT, Bakker BM. The fluxes through glycolytic enzymes in Saccharomyces cerevisiae are predominantly regulated at posttranscriptional levels. Proc Natl Acad Sci USA 2007, 104:15753-15758. 10.1073/pnas.0707476104, 2000426, 17898166.
38. Westerhoff HV. Signalling control strength. J Theor Biol 2008, 252:555-567. 10.1016/j.jtbi.2007.11.035, 18222488.
39. Hornberg JJ, Bruggeman FJ, Westerhoff HV, Lankelma J. Cancer: a systems biology disease. Biosystems 2006, 83:81-90. 10.1016/j.biosystems.2005.05.014, 16426740.
40. Boshoff HI, Barry CE, Hornberg J, Bruggeman F, Bakker B, Westerhoff H. Metabolic control analysis to identify optimal drug targets. Prog Drug Res 2007, 64:173-189.
41. Bakker BM, Assmus HE, Bruggeman F, Haanstra JR, Klipp E, Westerhoff H. Network-based selectivity of antiparasitic inhibitors. Mol Biol Rep 2002, 29:1-5. 10.1023/A:1020397513646, 12241036.
42. Westerhoff HV, Mosekilde E, Noe CR, Clemensen AM. Integrating systems approaches into pharmaceutical sciences. Eur J Pharm Sci 2008, 35:1-4. 10.1016/j.ejps.2008.05.011, 18602464.
43. Eddy A. Interstitial macrophages as mediators of renal fibrosis. Exp Nephrol 1995, 3:76-79.
44. Almeida I, Faria R, Vita P, Vasconcelos C. Systemic sclerosis refractory disease: From the skin to the heart. Autoimmun Rev 2011,
45. Hunninghake G. Sarcoidosis: linking inflammation and fibrosis. Am J Med Sci 1995, 309:124-133. 10.1097/00000441-199503000-00002, 7879816.
46. Selman M, Pardo A, Kaminski N. Idiopathic pulmonary fibrosis: aberrant recapitulation of developmental programs?. PLoS Med 2008, 5:e62. 10.1371/journal.pmed.0050062, 2265304, 18318599.
47. Vaglio A, Salvarani C, Buzio C. Retroperitoneal fibrosis. The Lancet 2006, 367:241-251.
48. Hindocha S, John S, Stanley JK, Watson SJ, Bayat A. The heritability of Dupuytren's disease: familial aggregation and its clinical significance. J Hand Surg Am 2006, 31:204-210. 10.1016/j.jhsa.2005.09.018, 16473680.
49. Fitzgerald AMP, Kirkpatrick JJR, Naylor IL. Dupuytren's disease - the way forward?. J Hand Surg Br 1999, 24:395-399. 10.1054/jhsb.1999.0207, 10473143.
50. Andrew JG, Andrew SM, Ash A, Turner B. An investigation into the role of inflammatory cells in Dupuytren's disease. J Hand Surg Br 1991, 16:267-271. 10.1016/0266-7681(91)90051-O, 1960491, 1960491.
51. Sugden P, Andrew JG, Andrew SM, Freemont AJ. Dermal dendrocytes in Dupuytren's disease: a link between the skin and pathogenesis?. J Hand Surg Br 1993, 18:662-666. 10.1016/0266-7681(93)90030-J, 7905015, 7905015.
52. Baird KS, Alwan WH, Crossan JF, Wojciak B. T-cell-mediated response in Dupuytren's disease. Lancet 1993, 341:1622-1623. 10.1016/0140-6736(93)90760-E, 8099992.
53. Gudmundsson KG, Arngrimsson R, Arinbjarnarson S, Olafsson A, Jonsson T. T- and B-lymphocyte subsets in patients with Dupuytren's disease. Correlations with disease severity. J Hand Surg Br 1998, 23:724-727. 10.1016/S0266-7681(98)80083-1, 9888668, 9888668.
54. Gabbiani G, Majno G. Dupuytren's contracture: fibroblast contraction? An ultrastructural study. Am J Pathol 1972, 66:131-146. 2032479, 5009249.
55. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 2002, 3:349-363. 10.1038/nrm809, 11988769.
56. Tomasek JJ, Vaughan MB, Haaksma CJ. Cellular structure and biology of Dupuytren's disease. Hand Clin 1999, 15:21-34.
57. Chang HY, Chi JT, Dudoit S, Bondre C, Van De Rijn M, Botstein D, Brown PO. Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc Natl Acad Sci USA 2002, 99:12877-12882. 10.1073/pnas.162488599, 130553, 12297622.
58. Kaufman L, Rousseeuw P. Finding Groups in Data: An Introduction to Cluster Analysis (Wiley Series in Probability and Statistics) 2005, Wiley-Interscience.
59. Iwasaki H, Müller H, Stutte HJ, Brennscheidt U. Palmar fibromatosis (Dupuytren's contracture). Ultrastructural and enzyme histochemical studies of 43 cases. Virchows Arch A Pathol Anat Histopathol 1984, 405:41-53. 10.1007/BF00694924, 6150573.
60. Kloen P. New insights in the development of Dupuytren's contracture: a review. Br J Plastic Surg 1999, 52:629-635. 10.1054/bjps.1999.3187, 10658134.
61. Alioto RJ, Rosier RN, Burton RI, Edward Puzas J. Comparative effects of growth factors on fibroblasts of Dupuytren's tissue and normal palmar fascia. J Hand Surg Am 1994, 19:442-452. 10.1016/0363-5023(94)90059-0, 8056971.
62. Badalamente MA, Hurst LC, Grandia SK, Sampson SP. Platelet-derived growth factor in Dupuytren's disease. J Hand Surg Am 1992, 17:317-323. 10.1016/0363-5023(92)90414-K, 1564283.
63. Badalamente MA, Sampson SP, Hurst LC, Dowd A, Miyasaka K. The role of transforming growth factor beta in Dupuytren's disease. J Hand Surg 1996, 21:210-215.
64. Bayat A, Alansar A, Hajeer AH, Shah M, Watson JS, Stanley JK, Ferguson MWJ, Ollier WER. Genetic susceptibility in Dupuytren's disease: lack of association of a novel transforming growth factor beta(2) polymorphism in Dupuytren's disease. J Hand Surg Br 2002, 27:47-49. 10.1054/jhsb.2001.0689, 11895345, 11895345.
65. Vaughan MB, Howard EW, Tomasek JJ. Transforming growth factor-[beta]1 promotes the morphological and functional differentiation of the myofibroblast. Exp Cell Res 2000, 257:180-189. 10.1006/excr.2000.4869, 10854066.
66. Berndt A, Kosmehl H, Mandel U, Gabler U, Luo X, Celeda D, Zardi L, Katenkamp D. TGF and bFGF synthesis and localization in Dupuytren's disease (nodular palmar fibromatosis) relative to cellular activity, myofibroblast phenotype and oncofetal variants of fibronectin. Histochem J 1995, 27:1014-1020.
67. Lappi DA, Martineau D, Maher PA, Florkiewicz RZ, Buscaglia M, Gonzalez AM, Farris J, Hamer M, Fox R, Baird A. Basic fibroblast growth factor in cells derived from Dupuytren's contracture: synthesis, presence, and implications for treatment of the disease. J Hand Surg Am 1992, 17:324-332. 10.1016/0363-5023(92)90415-L, 1314273.
68. Gonzalez AM, Buscaglia M, Fox R, Isacchi A, Sarmientos P, Farris J, Ong M, Martineau D, Lappi DA, Baird A. Basic fibroblast growth factor in Dupuytren's contracture. Am J Pathol 1992, 141:661-671. 1886703, 1325742.
69. Serini G, Gabbiani G. Mechanisms of myofibroblast activity and phenotypic modulation. Exp Cell Res 1999, 250:273-283. 10.1006/excr.1999.4543, 10413583.
70. Hu FZ, Nystrom A, Ahmed A, Palmquist M, Dopico R, Mossberg I, Gladitz J, Rayner M, Post JC, Ehrlich GD, Preston RA. Mapping of an autosomal dominant gene for Dupuytren's contracture to chromosome 16q in a Swedish family. Clin Genet 2005, 68:424-429. 10.1111/j.1399-0004.2005.00504.x, 16207209.
71. Brown JJ, Ollier W, Thomson W, Bayat A. Positive association of HLADRB1* 15 with Dupuytren's disease in Caucasians. Tissue Antigens 2008, 72:166-170. 10.1111/j.1399-0039.2008.01082.x, 18721277.
72. Bayat A, Walter J, Lambe H, Watson JS, Stanley JK, Marino M, Ferguson MWJ, Ollier WER. Identification of a novel mitochondrial mutation in Dupuytren's disease using multiplex DHPLC. Plast Reconstr Surg 2005, 115:134-141.
73. Murrell GA, Francis MJ, Bromley L. Free radicals and Dupuytren's contracture. Br Med J (Clin Res Ed) 1987, 28:1373-1375.
74. Qian A, Meals RA, Rajfer J, Gonzalez-Cadavid NF. Comparison of gene expression profiles between Peyronie's disease and Dupuytren's contracture. Urology 2004, 64:399-404. 10.1016/j.urology.2004.04.006, 15302515.
75. Satish L, Laframboise WA, O'Gorman DB. Identification of differentially expressed genes in fibroblasts derived from patients with Dupuytren's contracture. BMC Med Genomics 2008, 1:1-10. 10.1186/1755-8794-1-1, 2227949, 18237448.
76. Ulrich D, Ulrich F, Piatkowski A, Pallua N. Expression of matrix metalloproteinases and their inhibitors in cords and nodules of patients with Dupuytren's disease. Arch Orthop Trauma Surg 2009, 129:1453-1459. 10.1007/s00402-008-0726-3, 18758795.
77. Bayat A, Winder C, Stanley J, Day P, Goodacre R. Proteome analysis of dupuytren's disease differentiating between disease tissue phenotypes (nodule, cord and transverse palmar fascia) and control palmar fascia. J Hand Surg 2006, 31:5.
78. O'Gorman D, Howard JC, Varallo VM, Cadieux P, Bowley E, McLean K, Pak BJ, Gan BS. Identification of protein biomarkers in Dupuytren's contracture using surface enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF-MS). Clin Invest Med 2006, 29:136-145.
79. Kraljevic Pavelic S, Sedic M, Hock K, Vucinic S, Jurisic D, Gehrig P, Scott M, Schlapbach R, Cacev T, Kapitanovic S, Pavelic K. An integrated proteomics approach for studying the molecular pathogenesis of Dupuytren's disease. J Pathol 2009, 217:524-533. 10.1002/path.2483, 19089850.
80. Rhodes DR, Tomlins SA, Varambally S, Mahavisno V, Barrette T, Kalyana-Sundaram S, Ghosh D, Pandey A, Chinnaiyan AM. Probabilistic model of the human protein-protein interaction network. Nat Biotechnol 2005, 23:951-959. 10.1038/nbt1103, 16082366.
81. von Mering C, Jensen LJ, Kuhn M, Chaffron S, Doerks T, Krüger B, Snel B, Bork P. STRING 7 - recent developments in the integration and prediction of protein interactions. Nucleic Acids 2007, 35:D358-D362.
82. ter Kuile BH, Westerhoff HV. Transcriptome meets metabolome: hierarchical and metabolic regulation of the glycolytic pathway. FEBS Lett 2001, 500:169-171. 10.1016/S0014-5793(01)02613-8, 11445079.
83. Lazebnik Y. Can a biologist fix a radio? Or, what I learned while studying apoptosis. Cancer Cell 2002, 2:179-182. 10.1016/S1535-6108(02)00133-2, 12242150.
84. Emery AE. The muscular dystrophies. The Lancet 2002, 359:687-695.
85. Williams R, Mamotte C, Burnett J. Phenylketonuria: an inborn error of 1413 phenylalanine metabolism. Clin Biochem Rev 2008, 29:31-41. 2423317, 18566668.
86. Weigelt B, Reis-Filho JS. Histological and molecular types of breast cancer: is there a unifying taxonomy?. Nat Rev Clin Oncol 2009, 6:718-730. 10.1038/nrclinonc.2009.166, 19942925.
87. Westerhoff HV, Kolodkin A, Conradie R, Wilkinson SJ, Bruggeman FJ, Krab K, van Schuppen JH, Hardin H, Bakker BM, Moné MJ, Rybakova KN, Eijken M, van Leeuwen HJ, Snoep JL. Systems biology towards life in silico: mathematics of the control of living cells. J Math Biol 2009, 58:7-34. 10.1007/s00285-008-0160-8, 18278498.
88. Au-Yong ITH, Wildin CJ, Dias JJ, Page RE. A review of common practice in Dupuytren surgery. Tech Hand Up Extrem Surg 2005, 9:178-187. 10.1097/01.bth.0000186794.90431.a4, 16340578.
89. Badalamente MA, Hurst LC, Hentz VR. Collagen as a clinical target: nonoperative treatment of Dupuytren's disease. J Hand Surg 2002, 27:788-798.
90. Gilpin D, Coleman S, Hall S, Houston A, Karrasch J, Jones N. Injectable collagenase Clostridium histolyticum: a new nonsurgical treatment for Dupuytren's disease. J Hand Surg Am 2010, 35:2027-2038. 10.1016/j.jhsa.2010.08.007, 21134613.
91. Snoep JL, Bruggeman F, Olivier BG, Westerhoff HV. Towards building the silicon cell: a modular approach. Biosystems 2006, 83:207-216. 10.1016/j.biosystems.2005.07.006, 16242236.
92. Hucka M, Finney A, Sauro HM, Bolouri H, Doyle JC, Kitano H, Arkin AP, Bornstein BJ, Bray D, Cornish-Bowden A, Cuellar AA, Dronov S, Gilles ED, Ginkel M, Gor V, Goryanin II, Hedley WJ, Hodgman TC, Hofmeyr JH, Hunter PJ, Juty NS, Kasberger JL, Kremling A, Kummer U, Le Novère N, Loew LM, Lucio D, Mendes P, Minch E, Mjolsness ED, et al. The systems biology markup language (SBML): a medium for representation and exchange of biochemical network models. Bioinformatics 2003, 19:524-531. 10.1093/bioinformatics/btg015, 12611808.
93. Cuellar AA, Lloyd CM, Nielsen PF, Bullivant DP, Nickerson DP, Hunter PJ. An overview of CellML 1.1, a biological model description language. Simulation 2003, 79:740-747.
94. Jeong E, Nagasaki M, Saito A, Miyano S. Cell system ontology: representation for modeling, visualizing, and simulating biological pathways. In Silico Biol 2007, 7:623-638. 18467775, 18467775.
95. Demir E, Cary MP, Paley S, Fukuda K, Lemer C, Vastrik I, Wu G, D'Eustachio P, Schaefer C, Luciano J, Schacherer F, Martinez-Flores I, Hu Z, Jimenez-Jacinto V, Joshi-Tope G, Kandasamy K, Lopez-Fuentes AC, Mi H, Pichler E, Rodchenkov I, Splendiani A, Tkachev S, Zucker J, Gopinath G, Rajasimha H, Ramakrishnan R, Shah I, Syed M, Anwar N, Babur O, et al. The BioPAX community standard for pathway data sharing. Nat Biotechnol 2010, 28:935-942. 10.1038/nbt.1666, 3001121, 20829833.
96. Le Novère N, Hucka M, Mi H, Moodie S, Schreiber F, Sorokin A, Demir E, Wegner K, Aladjem MI, Wimalaratne SM, Bergman FT, Gauges R, Ghazal P, Kawaji H, Li L, Matsuoka Y, Villéger A, Boyd SE, Calzone L, Courtot M, Dogrusoz U, Freeman TC, Funahashi A, Ghosh S, Jouraku A, Kim S, Kolpakov F, Luna A, Sahle S, Schmidt E, et al. The Systems Biology Graphical Notation. Nat Biotechnol 2009, 27:735-741. 10.1038/nbt.1558, 19668183.
97. Hoops S, Sahle S, Gauges R, Lee C, Pahle J, Simus N, Singhal M, Xu L, Mendes P, Kummer U. COPASI - a COmplex PAthway SImulator. Bioinformatics 2006, 22:3067-3074. 10.1093/bioinformatics/btl485, 17032683.
98. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003, 13:2498-2504. 10.1101/gr.1239303, 403769, 14597658.
99. Calvano SE, Xiao W, Richards DR, Felciano RM, Baker HV, Cho RJ, Chen RO, Brownstein BH, Cobb JP, Tschoeke SK, Miller-Graziano C, Moldawer LL, Mindrinos MN, Davis RW, Tompkins RG, Lowry SF, . Inflamm and Host Response to Injury Large Scale Collab. Res. Program A network-based analysis of systemic inflammation in humans. Nature 2005, 437:1032-1037. 10.1038/nature03985, 16136080, Inflamm and Host Response to Injury Large Scale Collab. Res. Program.
100. Olivier BG, Snoep JL. Web-based kinetic modelling using JWS Online. Bioinformatics 2004, 20:2143-2144. 10.1093/bioinformatics/bth200, 15072998.
101. Le Novère N, Bornstein B, Broicher A, Courtot M, Donizelli M, Dharuri H, Li L, Sauro H, Schilstra M, Shapiro B, Snoep JL, Hucka M. BioModels Database: a free, centralized database of curated, published, quantitative kinetic models of biochemical and cellular systems. Nucleic Acids Res 2006, 34:D689-D691. 10.1093/nar/gkj092, 1347454, 16381960, 16381960.
102. Le Novère N, Finney A, Hucka M, Bhalla US, Campagne F, Collado-Vides J, Crampin EJ, Halstead M, Klipp E, Mendes P, Nielsen P, Sauro H, Shapiro B, Snoep JL, Spence HD, Wanner BL. Minimum information requested in the annotation of biochemical models (MIRIAM). Nat Biotechnol 2005, 23:1509-1515. 10.1038/nbt1156, 16333295.
103. Humphries M, Reynolds A. Cell-to-cell contact and extracellular matrix. Curr Opin Cell Biol 2009, 21:613-615. 10.1016/j.ceb.2009.09.001, 19773151.
104. van der Greef J, Hankemeier T, McBurney RN. Metabolomics-based systems biology and personalized medicine: moving towards n = 1 clinical trials?. Pharmacogenomics 2006, 7:1087-1094. 10.2217/14622416.7.7.1087, 17054418.
105. Kim YS, Maruvada P, Milner JA. Metabolomics in biomarker discovery: future uses for cancer prevention. Future Oncol 2008, 4:93-102. 10.2217/14796694.4.1.93, 18241004.
106. Hollywood K, Brison DR, Goodacre R. Metabolomics: current technologies and future trends. Proteomics 2006, 6:4716-4723. 10.1002/pmic.200600106, 16888765.